Oncimmune Holdings AAQS 2025

Mitä Oncimmune Holdings tekee?

Oncimmune Holdings PLC is a medical company based in the United Kingdom. It was founded in 2002 and has been listed on the London Stock Exchange since 2016. The company operates in the biotech industry and specializes in the research and development of tests for early cancer detection. The business model of Oncimmune aims to improve the survival chances of cancer patients through timely diagnosis and treatment. The development of various testing procedures is based on the understanding that the immune system changes when cancer cells form in the body. With this knowledge, Oncimmune has developed a range of tests based on the analysis of specific immune markers in the blood. The company is divided into two main areas: the diagnostic area and the immunomonitoring area. The diagnostic area focuses on the development of tests for early cancer detection, including tests for lung cancer, breast cancer, and liver cancer. The immunomonitoring area, on the other hand, focuses on monitoring the immune system to improve cancer therapy. A significant product from the diagnostic area of Oncimmune is the EarlyCDT-Lung test. The test is currently one of the most accurate blood tests for early lung cancer detection. It is based on the analysis of antibodies in the blood that are produced during the development of lung cancer. This test can detect changes in the blood years before the first symptoms of lung cancer appear. Another significant product of Oncimmune is the EarlyCDT test for breast cancer. This test has the potential to improve the diagnosis of breast cancer by providing more accurate results in women at high risk for breast cancer through a pretreatment. In the immunomonitoring area, Oncimmune offers a range of products and services aimed at improving the effectiveness of cancer therapies. This includes tests that analyze the immune system's response to cancer cells and predict the likelihood of success for immunotherapies. In summary, Oncimmune is an innovative medical company focused on the early detection and treatment of cancer. With the developed tests and services, Oncimmune has the potential to improve the lives of cancer patients. The company aims to increase the survival chances of cancer patients and improve the chances of recovery through better diagnosis and treatment. Oncimmune Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.